Search

Additional file 1: Figure S1. Glucose homeostasis in control and DIO mice. (a, b): Glucose tolerance was assessed by IPGTT. AUC above baseline was calculated as an index of glucose tolerance. (c-e): ELISA analyzed the levels of HbA1c, Hb and serum insulin. (f): weight gain after 16 weeks of HFD. The data are expressed as mean values ± SD. n=6 mice per group. *P < 0.05, **P < 0.01, ***P< 0.001. Figure S2. The identification of UC-MSCs. (a): Flow Cytometry results determining the UC-MSCs phenotype. UC-MSCs were stained with FITC-labeled CD14, CD19, CD73, HLA-DR and PE-labeled, CD34, CD45, CD90, CD105. Figure S3. Histomorphological changes of liver, skin and visceral fat. (a): Liver steatosis were analyzed through staining with Oil Red O (Scale bar, 200 μm). (b): H&E staining of skin (Scale bar, 1 mm). (c): H&E staining of visceral fat (Scale bar, 100 μm). Figure S4. Histomorphological changes of liver, skin and visceral fat. (a): Liver steatosis were analyzed through staining with Oil Red O (Scale bar, 200 μm). (b): H&E staining of skin (Scale bar, 1 mm). (c): H&E staining of visceral fat (Scale bar, 100 μm). Figure S5. The effect of UC-MSCs combined with FMD on blood glucose and body weight in db/db mice. (a-c): Blood glucose and body weight were determined after fasting 6h at sacrificed. The data are expressed as mean values ± SD. n=6 mice per group. *P < 0.05, **P < 0.01, ***P< 0.001.

Additional file 1.